First-in-class mucosal therapy neutralizing viruses at the point of entry. Clinically proven to reduce viral load and accelerate recovery for respiratory infections.
AD17002 supports antiviral therapy for respiratory viral infections. Two Phase IIa clinical trials evaluating treatments for SARS-CoV-2 infection have demonstrated a favorable safety profile (NCT05541510, NCT05069610). Importantly, the therapy has shown meaningful clinical benefits, including earlier viral clearance and reduced time to symptom resolution, highlighting its potential to modify the course of the disease and its symptoms. By activating mucosal immunity at the primary site of viral entry while reinforcing immune responses, it addresses the limitations of conventional injectable approaches. As a first-of-its-kind mucosal therapy, AD17002 offers a novel MOA with strong clinical relevance and significant commercial potential in the evolving landscape of respiratory antivirals.
Covid-19 Immunotherapy — Phase IIa (NCT05069610) AD17002 treatment reduces viral load and shortens time to symptom resolution.
Publications:
doi.org/10.1080/21645515.2024.2432105
Manuscript submitted
back to overview
